The RAMP2/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells  by Kamitani, Shigeki et al.
The RAMP2/CRLR complex is a functional adrenomedullin receptor in
human endothelial and vascular smooth muscle cells
Shigeki Kamitani, Makoto Asakawa, Yoshiyuki Shimekake, Kenji Kuwasako,
Koichiro Nakahara, Tsuneaki Sakata*
Shionogi Institute for Medical Science, Shionogi and Co. Ltd., 2-5-1, Mishima, Settsu-shi, Osaka 566-0022, Japan
Received 19 February 1999; received in revised form 5 March 1999
Abstract Adrenomedullin, a potently hypotensive peptide iso-
lated from human pheochromocytoma, is known to elicit a rise in
cAMP levels within mammalian endothelial and smooth muscle
cells. Until now, however, little has been known about the
adrenomedullin receptor. Recently, a group called receptor
activity-modifying proteins that complex with the calcitonin
receptor-like receptor, and thereby regulate its transport and
ligand specificity, were identified. Here we show that mRNA for
both the calcitonin receptor-like receptor and the receptor
activity-modifying protein 2, but not the receptor activity-
modifying protein 1 or receptor activity-modifying protein 3,
are expressed in human endothelial and vascular smooth muscle
cells. We also found that adrenomedullin increased cAMP levels
in HeLa EBNA and 293 EBNA cells, expressing both the
receptor activity-modifying protein 2 and calcitonin receptor-like
receptor proteins. Thus, the receptor activity-modifying protein
2/calcitonin receptor-like receptor complex apparently serves as
a functional adrenomedullin receptor in human endothelial and
vascular smooth muscle cells.
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1. Introduction
Adrenomedullin, which is isolated from human pheochro-
mocytoma, is a member of the calcitonin gene-related peptide
(CGRP) family [1]. It is known to be potently hypotensive in
rat and it evokes a rise in the levels of cAMP within mamma-
lian endothelial, smooth muscle [1^4] and mesangial cells [5,6].
At present, however, little is known about the adrenomedullin
receptor. Kapas et al. isolated a G-protein-coupled receptor
homologue of the canine orphan receptor (RDC-1) from rat
lung and, on the basis of its pharmacology, identi¢ed it as an
adrenomedullin receptor [7,8]. But Kennedy et al. showed that
neither this putative rat adrenomedullin receptor nor its hu-
man counterpart [9] was functional when expressed in COS-7
cells, indicating that they were not authentic adrenomedullin
receptors [10]. Recently, McLatchie et al. reported that the
calcitonin receptor-like receptor (CRLR) could function as
either a CGRP receptor or an adrenomedullin receptor, de-
pending on the expression of receptor activity-modifying pro-
teins (RAMPs) (members of a new family of single transmem-
brane domain proteins) [11]. They proposed that whereas
the RAMP1/CRLR complex serves as a CGRP receptor,
RAMP2/CRLR serves as an adrenomedullin receptor. How-
ever, con¢rmation of the model through demonstration of the
co-expression of CRLR and RAMP2 mRNA in adrenome-
dullin-sensitive cells has until now not been reported. Our
present study, therefore, is the ¢rst to show that expression
of both CRLR and RAMP2 is required for constituting func-
tional adrenomedullin receptors.
2. Materials and methods
2.1. Materials
Human aortic smooth muscle cells (HASMCs), human aortic endo-
thelial cells (HAECs) and human umbilical vascular endothelial cells
(HUVECs) as well as Smooth Muscle Cell Basal Medium (SmBM)
and Endothelial Cell Basal Medium (EBM) were all purchased from
Clonetics Corp/Sanko Junyaku (Tokyo, Japan). Human adrenome-
dullin and CGRP were obtained from Peptide Institute (Osaka, Ja-
pan). Bovine serum albumin and 3-isobutyl-1-methylxanthine (IBMX)
were from Sigma (St. Louis, MO, USA). Other reagents were from
Nacalai Tesque (Kyoto, Japan).
2.2. Plasmids
A plasmid-cloned, complete CRLR cDNA was a gift from Dr
Kangawa of the National Cardiovascular Research Institute (Suita,
Japan). RAMP cDNAs were cloned from a human embryonic cDNA
library (Clontech, Palo Alto, CA, USA) by PCR using the following
sets of primers: RAMP1, 5P-CGA GCG GAC TCG ACT CGG CAC
CGC T-3P and 5P-GCC TGG GCC CCG CCT ACA CAA TGC C-3P ;
RAMP2, 5P-CTC CTT GCT GCA CGA TGG CCT C-3P and 5P-TTG
TTG AGA AGC TCG TGC CCC CTA G-3P ; RAMP3, 5P-CAG
CCA TGG AGA CTG GAG CGC TGC-3P and 5P-ATC TCA
CCG GGA CCC TCA CAG CAG C-3P. The RAMP cDNAs were
then subcloned into a pCAGGS vector [12] carrying the neomycin
resistance gene. CRLR cDNA was subcloned into a pDREF vector
[13] also containing the EB virus nuclear antigen (EBNA-1) and the
EB virus origin (Ori P), which enable high-copy episomal replication,
and the hygromycin-B resistant gene, which is maintained extra-chro-
mosomally and expresses high levels of recombinant proteins under
the control of the human elongation factor 1K (EF-1K) promoter.
2.3. Cell culture and cDNA transfection
HASMCs were cultured in SmBM supplemented with human epi-
dermal growth factor (0.5 ng/ml), human ¢broblast growth factor-B (2
ng/ml), insulin (5 Wg/ml), 5% fetal bovine serum, 50 ng/ml gentamicin
and 50 Wg/ml amphotericin-B. HAECs and HUVECs were cultured in
EBM supplemented with human epidermal growth factor (0.5 ng/ml),
human ¢broblast growth factor-B (2 ng/ml), bovine brain extracts (12
Wg/ml), hydrocortisone (1.0 Wg/ml), 5% fetal bovine serum, 50 ng/ml
gentamicin and 50 Wg/ml amphotericin-B. HeLa EBNA cells and 293
EBNA cells (subclones of HeLa and 293 cells engineered to express
EBNA-1 and to carry the neomycin resistance gene) were cultured in
DMEM supplemented with 10% fetal bovine serum, 10% sodium
glutamate, 100 Wg/ml penicillin G, 100 U/ml streptomycin, 50 Wg/ml
amphotericin-B and 400 or 250 Wg/ml geneticin. Cells were incubated
at 37‡C under an atmospheric 95% air/5% CO2. HeLa EBNA cells
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and 293 EBNA cells expressing CRLR were generated by hygromy-
cin-B selection of cells transfected with plasmids encoding CRLR and
a selection marker. For transient expression, cells were plated in six
well plates to a density of 1^5U105 cells/well and transfected with 1 Wg
plasmid/well. Transfection was carried out using LipofectAmine
according to the manufacturer’s instructions (Gibco BRL, Grand Is-
land, NY, USA).
2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was prepared from the cultured cells using Trizol Re-
agent (Gibco BRL) and 5 Wg aliquots were then subjected to reverse
transcription using a Superscript II cDNA synthesis kit (Gibco BRL).
CRLR and RAMP mRNAs were detected by nested PCR using a set
of speci¢c primers (Fig. 2A). All ¢rst PCRs were carried out on a
Omnigene temperature cycler (HYBAID, Middlesex, TW, USA) using
the following protocol: an initial denaturation step at 95‡C for 5 min
was followed by 30 cycles at 95‡C for 30 s, 55‡C for 30 s and 72‡C for
30 s. Nested PCRs were then performed using the same protocol and
1 Wl of the ¢rst PCR products as a template. A set of GAPDH
primers was used as a control for the RT-PCR (Fig. 2A).
2.5. Measurement of cAMP
Intracellular cAMP was measured as reported previously [14].
Brie£y, cells were washed twice with Hanks’ balanced salts containing
20 mM HEPES (pH 7.4), 0.1% bovine serum albumin and 0.5 mM
IBMX and then incubated in the same solution for 15 min in the
presence or absence of ligand. The cells were then lysed in 6% tri-
chloroacetic acid, after which the acid was removed by water-satu-
rated diethyl ether extraction. The aqueous phase was then lyophilized
and cAMP was measured using the Biotrack cAMP EIA assay kit
(Amersham-Pharmacia, Little Chalfont, UK).
2.6. Statistics
All values were expressed as mean þ S.D. The statistical signi¢cance
of di¡erences among cells was evaluated using unpaired ANOVA and
Students’ t-tests. Values of P6 0.05 were considered signi¢cant.
3. Results and discussion
3.1. Adrenomedullin selectively induced intracellular cAMP
accumulation
We initially con¢rmed that adrenomedullin signi¢cantly
and dose-dependently increased cAMP levels in HAECs, HU-
VECs and HASMCs (Fig. 1A). CGRP, by contrast, had no
e¡ect on the cAMP levels in human cells (Fig. 1B), even
though it elevated cAMP in rat vascular smooth muscle cells
(data not shown). In HeLa EBNA and 293 EBNA cells of
human origin, neither adrenomedullin nor CGRP increased
cAMP. Thus, the adrenomedullin receptor appears to be spe-
ci¢cally expressed in HAECs, HUVECs and HASMCs.
3.2. RAMP2 and CRLR mRNA are both expressed in HAECs,
HUVECs and HASMCs
To determine whether the adrenomedullin-sensitive, human
endothelial and smooth muscle cells express both CRLR and
RAMPs, we examined the expression of their mRNAs by RT-
PCR. Speci¢c primer sets for CRLR and RAMPs were de-
signed (Fig. 2A) and total RNA was extracted from the cells
assayed in Fig. 1. After cDNA synthesis by reverse transcrip-
tion, nested PCR was carried out. Co-expression of CRLR
and RAMP2 mRNA was detected in adrenomedullin-sensitive
HAECs, HUVECs and HASMCs (Fig. 2B), but only RAMP2
mRNA was expressed in 293 EBNA cells and HeLa EBNA
cells did not express either mRNA. This is consistent with the
notion that when complexed, CRLR and RAMP2 comprise a
functional adrenomedullin receptor. Neither RAMP1 nor
RAMP3 mRNA was detected in any of the cells in this study
in agreement with the results in Fig. 1.
3.3. The RAMP2/CRLR complex is a functional
adrenomedullin receptor
To con¢rm that all else is equal, the speci¢city of the CRLR
receptor could be de¢ned entirely by the expression mode of
RAMPs, cells constitutively expressing CRLR were con-
structed from HeLa EBNA and 293 EBNA cells as described
in Section 2. These CRLR-expressing cells were transiently
transfected with the respective RAMP cDNAs and the resul-
tant transfectants were stimulated with either adrenomedullin
or CGRP. Modulation of the receptor speci¢city was assessed
on the basis of changes in intracellular cAMP levels. Fig. 3
shows that RAMP2 and CRLR reconstitute a functional
adrenomedullin receptor in both HeLa EBNA and 293
EBNA cells, as indicated by the adrenomedullin-evoked accu-
mulation of cAMP (A and C, solid bars). The RAMP2/CRLR
complex was selective for adrenomedullin, making this the
direct observation that the RAMP2/CRLR complex serves
as a functional adrenomedullin receptor. The RAMP1/
CRLR and RAMP3/CRLR complexes were sensitive to
both adrenomedullin and CGRP (dotted and open bars),
the former being equally sensitive or relatively more speci¢c
to CGRP and the latter more sensitive to adrenomedullin, but
neither RAMP1 nor RAMP3 was detected in adrenomedullin-
sensitive cells (Fig. 2B). We also observed that HAECs, endo-
genously expressing only RAMP2, became sensitive to CGRP
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Fig. 1. The e¡ect of adrenomedullin and CGRP on intracellular
cAMP levels. Dose response curves showing intracellular cAMP ac-
cumulation in response to adrenomedullin (A) and CGRP (B).
HAECs (open squares), HUVECs (closed squares), HASMCs (open
circles), HeLa EBNA cells (open triangles) and 293 EBNA cells
(closed triangles) were each incubated with 0^1037 M adrenomedul-
lin or CGRP for 15 min. Intracellular cAMP levels were then meas-
ured using a cAMP EIA kit. *P6 0.05 versus basal levels.
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Fig. 2. Expression of RAMP and CRLR mRNA in human endothelial and smooth muscle cells. A: Primer sets used in the experiment. B:
RT-PCR showing expression of RNAs for RAMP1, RAMP2, RAMP3 and CRLR in HeLa EBNA cells (lane 1), HASMCs (lane 2), HUVECs
(lane 3), HAECs (lane 4) and 293 EBNA cells (lane 5). Total RNA from 293 EBNA cells transfected with the respective cDNAs was used as a
positive control. After cDNA synthesis, nested PCR was performed using four sets of speci¢c primers. Primers for GAPDH served as an inter-
nal control. The ¢nal PCR products were cloned and identi¢ed by DNA sequencing.
Fig. 3. RAMP-dependent modulation of the ligand speci¢city. RAMPs were expressed in 293 EBNA and HeLa EBNA cells either together
with CRLR (A and C, respectively) or alone (B and D, respectively). Cells were then transiently transfected with RAMP1 (dotted bars),
RAMP2 (solid bars), RAMP3 (open bars) or vector plasmid (hatched bars). The transfectants were incubated for 15 min in the absence of li-
gand (0) or in the presence of 1038 M adrenomedullin (A) or 1038 M CGRP (C) and intracellular cAMP levels were measured by the cAMP
EIA kit. *P6 0.05 (A or C versus 0); 2 : P6 0.05 (A versus C).
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by transfection with RAMP1 cDNA (data not shown). These
results suggest that the degree of relative expression levels of
the RAMPs family regulates the receptor speci¢city of CRLR.
The magnitudes of the maximal responses to adrenomedullin
were greater in endothelial cells than in smooth muscle cells
(Fig. 1), a di¡erence that likely re£ects the respective levels of
RAMP2 mRNA expression. Using Northern blots, RAMP2
was detected in endothelial cells but not in other cell types
(data not shown). Moreover, 293 EBNA cells expressed
RAMP2 mRNA prior to transfection, so that adrenomedul-
lin, but not CGRP, dose-dependently evoked cAMP accumu-
lation in cells constitutively expressing CRLR (data not
shown). When the same cell type was then transiently trans-
fected with RAMP2 cDNA, both the RAMP2 mRNA level
and the evoked accumulation of cAMP were augmented.
Thus, the stoichiometric ratio between RAMP2 and CRLR
may be crucial in determining the responsiveness of cells to
adrenomedullin. CRLR has three putative N-glycosylation
sites at the amino-terminal and it has been suggested that
RAMPs regulate the CRLR transport by modifying the level
of its glycosylation [1]. In that regard, co-expression of
RAMP1 and CRLR leads to terminal glycosylation of the
CRLR, whereas expression of RAMP2 results in only core
glycosylation. Receptor speci¢city may also be determined
by glycosylation. For example, selectivity of the calcitonin
receptor for either amylin or calcitonin is apparently glycosy-
lation-dependent [15]. In analogous fashion, the heterodime-
rization required for the formation of functional gamma-ami-
nobutyric acid (GABA)B receptors is dependent on the co-
expression of GABABR1 and GABABR2. Of those,
GABABR1 is terminally glycosylated and expressed at the
cell surface where it complexes with GABABR2 [16]. Thus,
RAMPs appear to contribute to the oligomerization, the func-
tionality and the ligand speci¢city of CRLR receptors. The
precise characterization of speci¢c relationships between the
expression of RAMP and of CRLR and the role of CRLR N-
glycosylation in the receptor function will require further
study.
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